<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782977</url>
  </required_header>
  <id_info>
    <org_study_id>B2008:129</org_study_id>
    <nct_id>NCT00782977</nct_id>
  </id_info>
  <brief_title>Apneic Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia</brief_title>
  <official_title>Oxygenation Via Nasal Cannulae Prevents Arterial Hypoxemia During the Apneic Period in Paralyzed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effectiveness of continuous oxygen provided by&#xD;
      nasal prongs in preventing or delaying hypoxemia during the apneic period that occurs after&#xD;
      induction of general anesthesia. This will be evaluated by measuring the arterial oxygen&#xD;
      tension (PaO2).&#xD;
&#xD;
      The study will also evaluate whether there is any difference in PaO2 when using nasal prongs&#xD;
      with flow rates of 5 L/minute versus 10 L/minute of oxygen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Certain patient populations are at risk for rapid desaturation and the rapid development of&#xD;
      hypoxemia (eg. morbidly obese and pregnant patients). Using pulse oximetry, it has already&#xD;
      been shown that oxygen provided with a catheter inserted into the nasopharynx is effective in&#xD;
      delaying the desaturation that occurs with apnea before the trachea is intubated. It has also&#xD;
      been shown that apneic oxygenation with nasal prongs at 5 L/min during fibreoptic intubation&#xD;
      can delay the onset of hypoxemia.&#xD;
&#xD;
      The study will evaluate whether there is any significant difference in the PaO2 (arterial&#xD;
      oxygen tension, as measured by an arterial blood gas) when nasal prongs are used to provide&#xD;
      apneic oxygenation in paralyzed patients at flows of 5 L/min compared to 10 L/min.&#xD;
&#xD;
      The study aims to demonstrate that apneic oxygenation using nasal prongs is effective in&#xD;
      preventing or delaying hypoxemia (by measuring PaO2), and that this technique may be used to&#xD;
      prevent morbidity and mortality in all clinical areas (not only in the Operating Room&#xD;
      environment) where airway management is undertaken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2 in mmHg (arterial oxygen tension as measured by an arterial blood gas)</measure>
    <time_frame>Arterial blood gases taken at one minute intervals post induction in the apneic period, for a total of 4 measurements</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypoxia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Nasal cannulae with no oxygen flow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal cannulae with oxygen flow at 5 L/minute</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal cannulae with oxygen flow at 10 L/minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal oxygen therapy</intervention_name>
    <description>Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females&#xD;
&#xD;
          2. ASA Class 1-3&#xD;
&#xD;
          3. Ages of 18 to 65&#xD;
&#xD;
          4. Elective surgery under general anesthesia&#xD;
&#xD;
          5. No evidence of significant cardiac, respiratory or gastrointestinal disease&#xD;
&#xD;
          6. No contraindications to the insertion of a radial arterial catheter&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of a difficult airway (expected difficult intubation identified from patient&#xD;
             history or clinical examination)&#xD;
&#xD;
          2. Features suggestive of difficult bag mask ventilation&#xD;
&#xD;
          3. Significant GERD requiring medical therapy&#xD;
&#xD;
          4. Significant respiratory disease (including severe asthma or COPD, oxygen dependency,&#xD;
             pulmonary hypertension)&#xD;
&#xD;
          5. Significant cardiac disease (ischemic heart disease, severe aortic and mitral stenosis&#xD;
             and/or regurgitation, EF &lt; 50% if known)&#xD;
&#xD;
          6. Inability to lie flat (skeletal deformities, orthopnea, congestive cardiac failure)&#xD;
&#xD;
          7. PaO2 &lt; 200 mmHg on ABG after adequate preoxygenation to an ETO2 &gt; 85%&#xD;
&#xD;
          8. Hemoglobin &lt; 100 g/L&#xD;
&#xD;
          9. BMI &gt; 40 kg/ m2&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Patient unwillingness or refusal to participate&#xD;
&#xD;
         12. Inability to consent (dementia) or cooperate (mentally challenged)&#xD;
&#xD;
         13. Inability to communicate well or to understand English (language barrier, dysphasia)&#xD;
&#xD;
         14. Neuromuscular disorders&#xD;
&#xD;
         15. Known or presumed cervical spine instability (cervical spine fractures, rheumatoid&#xD;
             arthritis)&#xD;
&#xD;
         16. Patients undergoing neurosurgical procedures&#xD;
&#xD;
         17. Any clinical or radiological evidence of increase in intracranial pressure&#xD;
&#xD;
         18. Any requirement for rapid sequence intubation&#xD;
&#xD;
         19. Inability to tolerate the apneic period&#xD;
&#xD;
         20. Allergy to any of the agents used for induction of general anesthesia in the study&#xD;
&#xD;
         21. Arterial insufficiency with poor collateral circulation to the hand (tested with&#xD;
             Doppler ultrasound or clinically by palpation with the Allen test)&#xD;
&#xD;
         22. Inability to cannulate an artery for monitoring and sampling purposes&#xD;
&#xD;
         23. Uncorrected coagulopathy&#xD;
&#xD;
         24. Baseline hypercarbia (PaCO2 &gt; 50 mmHg)&#xD;
&#xD;
         25. Known or suspected obstructive sleep apnea&#xD;
&#xD;
         26. Significant nasal obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Christodoulou, MBChB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Anesthesia and Perioperative Medicine, St. Boniface General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr Chris Christodoulou</name_title>
    <organization>Dept. of Anesthesia and Perioperative Medicine, St. Boniface General Hospital</organization>
  </responsible_party>
  <keyword>Apneic oxygenation</keyword>
  <keyword>Apneic diffusion oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

